ClinicalTrials.gg
WithdrawnNCT06702280Updated Sep 30, 2026

Assessing the Safety of an IGY Supplement on the Gut Microbiome

A Phase 1/2 interventional study of IgY supplement and Placebo in Healthy and Microbiome, sponsored by Nimble Science Ltd.. Withdrawn at 1 site in Canada. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Nimble Science Ltd. · Phase 1/2, Interventional, and Basic science

How we know

Why this study was withdrawn
Sponsor cancelation
Updated Sep 30, 2026Now WithdrawnStart date moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study is to evaluate whether Muno-IgY is effective in enhancing immune health among adults over a six week period.

Read the detailed description

The goal of this single-arm interventional trial is to evaluate the safety and effectiveness of Muno-IGY in a sample population of 20 healthy adults over a six week period. The intervention will be compared to a baseline before ingestion of the supplement with both qualitative questionnaires, a daily diary, and microbiome data gathered by the SIMBA and LIMBA capsules.

02

Conditions studied

  • Healthy
  • Microbiome
03

In context

Lead sponsor

Nimble Science Ltd. is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18-65 years old at the inclusion of the study, both female and male subjects.
  2. Signed ; willing and able to comply with study procedures.
  3. Willing to maintain their diet and physical activity levels during the study.
  4. Able to swallow a 25mm x 9mm sized capsule

Exclusion criteria

Exclusion Criteria:

  1. Use of regular prescription medications, including antihypertensives, anti-inflammatory drugs, , , antidepressants, antipsychotics, anti-diabetic medications, and anti-arrhythmic agents, which in the opinion of the investigator, would adversely affect study safety or outcome.
  2. Prior gastrointestinal disease, surgery, or radiation treatment which, in the Investigator's opinion, would lead to intestinal structuring or obstruction with a risk of capsule non-excretion, including, e.g., achalasia, eosinophilic esophagitis, cancer diagnosis or previous esophageal, gastric, small intestinal, or colonic surgery. Appendectomy or cholecystectomy more than 3 months before the screening visit is acceptable.
  3. History of known structural gastrointestinal abnormalities such as structures or fistulas which may lead to mechanical obstruction.
  4. Use of any medications in the week prior to the SIMBA or LIMBA capsule ingestions, unless part of regular treatment, that could substantially alter gastrointestinal motor function (e.g., opioids, anticholinergics, GLP-1 analogues); laxative and prokinetic use is allowed if it is kept unchanged in the week prior to the SIMBA and LIMBA capsule ingestions. Proton pump inhibitors (PPIs) are allowed provided a of 48 hours is respected before swallowing the capsules and PPI treatment is resumed only 4 hours thereafter.
  5. Organic motility disorder, including gastroparesis, intestinal pseudo-obstruction, systemic sclerosis, Ogilvie's syndrome.
  6. Any significant gastrointestinal, heart, liver, lung, kidney, blood, endocrine or nervous system disease, which in the opinion of the investigator, would adversely affect study safety or outcome.
  7. Cancer diagnosis or treatment within the past year (non-melanoma skin cancers are acceptable).
  8. History or diagnosis of immunological or infectious disease (hepatitis, tuberculosis, , Parkinson's).
  9. History of oropharyngeal dysphagia, or other swallowing disorder with a risk of capsule aspiration.
  10. Antibiotic use (except for topical use) ≤ 12 weeks prior to screening. Potential participants may be eligible once a 12-week washout is completed.
  11. Consumption of probiotic or prebiotic supplements within 1 month prior to screening. Potential participants may be eligible once a 1-month washout is completed.
  12. Any prior Fecal Microbiota Transplantation.
  13. Colon cleanses/bowel prep for 2 weeks
  14. Pregnant or breastfeeding.
  15. Planning to become pregnant.
  16. Alcohol or drug abuse.
  17. Egg allergy
  18. Vegan diet, or other diet where ingestion of eggs is not suitable
  19. History of less than 3 bowel movements per week.
  20. Are scheduled for an MRI at any time during the study. Potential participants may be eligible to participate once their MRI procedure is completed
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    IgY Supplement

    Participants will ingest the IgY supplement on a daily basis

    Dietary Supplement: IgY supplement

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Dietary supplementIgY supplement

    Ingesting the immune supplement over the experimental period

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Primary Outcome

    To assess the safety of Muno-IgY™ in the small intestine. By monitoring the number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    Time frame: Through study completion (Baseline to the end of the interventional period), an average of 6 weeks

Secondary outcomes

  1. Secondary 1

    Investigate the association or determine if changes in the small and large intestine occur and fecal microbiomes through metagenomic analysis

    Time frame: Through study completion (Baseline to the end of the interventional period), an average of 6 weeks

  2. Secondary 2

    To assess the bioavailability of the Muno-IgY, using the SIMBA capsule as a tool for sample collection

    Time frame: Through study completion (Baseline to the end of the interventional period), an average of 6 weeks

07

Study locations

1 site
  • Nimble Science
    Calgary, Alberta T2L 1Y8, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jan 2026; primary completion for Oct 2026, 9 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: start Feb 2025 → Jan 2026, primary completion Oct 2025 → Oct 2026 and completion Oct 2025 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2024
First posted
Nov 22, 2024
StartEst.
Jan 2026was Feb 2025
Primary completionEst.
Oct 2026was Oct 2025
CompletionEst.
Oct 2027was Oct 2025
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Withdrawn Sponsor cancelation
changed Sep 30, 2026
Start date
Feb 2025→Jan 2026
Sep 30, 2026
Primary completion
Oct 2025→Oct 2026
Sep 30, 2026
Study completion
Oct 2025→Oct 2027
Sep 30, 2026
Enrollment
20 (estimated)→0 (actual)
Sep 30, 2026
Interventions
Added Drug: Placebo. Arms added: Placebo
Sep 30, 2026
Design
Added Phase 2
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Not yet recruiting→Withdrawn
    Why stopped Sponsor cancelation
    Start date Feb 2025→Jan 2026
    Primary completion Oct 2025→Oct 2026
    Study completion Oct 2025→Oct 2027
    Enrollment 20 (estimated)→0 (actual)
    Interventions Added Drug: Placebo. Arms added: Placebo
    Design Added Phase 2
    + 3 other changes: responsible party, oversight details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06702280
Lead sponsor
Nimble Science Ltd.
Responsible party
Sponsor
First posted
Nov 22, 2024
Start date
Jan 2026 (estimated)
Primary completion
Oct 2026 (estimated)
Completion
Oct 2027 (estimated)
Last update
Sep 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion